A new targeted therapy has shown promise for a difficult-to-treat subset of lung cancer. In a multinational phase 2 trial, the oral drug sunvozertinib produced durable tumor responses in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to research published Sept. 9 in the Journal of Clinical Oncology . The findings supported the FDA’s July 2025 decision to grant the drug, marketed as Zegfrovy and manufactured by Dizal Pharmaceutical Co., Ltd., accelerated approval for this use.

EGFR exon 20 insertion mutations make up only a small share of NSCLC cases, amounting to approximately 2% to 3% of the cases overall and roughly 12% of all EGFR-related tumors. NSCLC cases with mutations are especially tough to treat and have hi

See Full Page